Browser does not support script.
Birmingham has been at the forefront of transplants since the pioneering work of Sir Peter Medawar. Our researchers are continuing his legacy.
Developing the use of sensors and clocks in innovative, ground-breaking technologies to change the future landscapes of healthcare, transport, defence, civil engineering and more.
Academia partnering with business, investigating, developing and co-creating robust and innovative solutions to achieve responsible business success. Building the foundations for a more responsible and sustainable future.
We are working with partners across the globe to understand how to save lives at risk from poor air quality.
Challenging established views and policy responses to migration and its impact on societies in a rapidly changing world.
Birmingham academics work on major issues in international ethics and global justice and train the next generation of students to tackle these issues.
We explore what it means to be human – in historical and cultural contexts, within ethical and legal norms and through languages and communication.
From atoms to astronomy, computers to cars and robots to robust materials, our goal is to transform our understanding of the world to make life easier, healthier and more sustainable.
Across the breadth of life and environmental sciences we discover, apply and translate science, forging major advances in human and environmental health.
With over 1,000 academic staff researchers and around £80 million new research funding per year, we are dedicated to performing world-leading research with the ultimate goal of improving human health.
We address the challenges facing society and the economy, from shedding light on the refugee crisis, to character education in schools, through to developing leaders in the NHS.
Despite the existence of treatments, tuberculosis (TB) continues to present a major healthcare challenge, accounting for nearly nine million new infections and over one million deaths each year.
The global health threat from TB continues to grow given the increasing prevalence of Multi Drug Resistant (MDR) TB strains that are resistant to at least two of the main first-line TB drugs – isoniazid and rifampicin – and Extensively Drug Resistant (XDR) TB strains that are resistant to three or more of the six classes of second-line drugs.
With this need in mind, aiming to target drug-resistant strains of tuberculosis, the CooperaTB ITN-EID project focuses on two new biological mechanisms: decaprenylphosphorylarabinose (DPA) synthesis and aspartyl tRNA synthetase (AspRS).
PhD Students and Staff in the CooperaTB Project
A Range of Helpful Scientific Resources